Overview

A Study of Regorafenib Combined With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard Treatment

Status:
NOT_YET_RECRUITING

Trial end date:
2028-07-30

Target enrollment:

Participant gender:

Summary

This study is a multicenter, prospective, randomized controlled Phase II clinical trial. The primary endpoint is to evaluate the efficacy and safety of regorafenib combined with envafolimab compared to physician's choice in patients with metastatic gastrointestinal stromal tumors harboring KIT exon 17 mutations who have failed standard treatments.

Phase:

PHASE2

Details

Lead Sponsor:

Peking University

Treatments:

Control Groups
envafolimab